International consultancy Accenture announced last week that it had invested in AI startup Alembic, kickstarting a partnership that will leverage the technology to better measure the effectiveness of ...

Alembic Pharmaceuticals Limited (Alembic), a vertically integrated research and development pharmaceutical company, announced that it has received final approval from the US Food & Drug Administration ...

Alembic Pharmaceuticals share price rose 2 percent in the opening trade on November 17 following the company received final approval from USFDA for angina drug. At 09:19am, Alembic Pharmaceuticals was ...

Led by Prysm Capital and Accenture with participation from Silver Lake Waterman, Liquid 2 Ventures, NextEquity, Friends & Family Capital, and WndrCo, this round positions Alembic among the top AI labs ...

Recent research from Gartner found that two-thirds of marketing leaders reported moderate to significant challenges demonstrating the impact of marketing campaigns on business outcomes to key ...

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diltiazem ...

Alembic Pharmaceuticals said that it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Diltiazem Hydrochloride Tablets USP. The ...

Alembic Pharmaceuticals Limited (Alembic), a vertically integrated research and development pharmaceutical company, announced that it has received final approval from the US Food & Drug Administration ...

Causal artificial intelligence startup Alembic Technologies Inc. said today it has raised $145 million in a Series B growth round that increases its valuation almost 16-fold. It’s using a big chunk of ...

Alembic Technologies has raised $145 million in Series B and growth funding at a valuation 15 times higher than its previous round, betting that the next competitive advantage in artificial ...

Alembic Pharmaceuticals is expanding its presence in the United States through a broader portfolio of complex generics, injectables, and an entry into branded drugs following the acquisition of ...